mRNA-1273 COVID-19 vaccine candidate
GPTKB entity
Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:age |
6 months and older (in some regions)
|
| gptkbp:antigen |
gptkb:SARS-CoV-2_spike_protein
|
| gptkbp:approvedBy |
2020-12-18
|
| gptkbp:ATCCode |
gptkb:J07BX03
|
| gptkbp:boosters |
yes
|
| gptkbp:brand |
gptkb:Spikevax
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:contains |
lipid nanoparticles
nucleoside-modified mRNA |
| gptkbp:developedBy |
gptkb:Moderna
gptkb:National_Institute_of_Allergy_and_Infectious_Diseases |
| gptkbp:effect |
~94% (original strain, clinical trials)
|
| gptkbp:emergencyServices |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
2 doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
mRNA-1273 COVID-19 vaccine candidate
|
| gptkbp:legalStatus |
Prescription only
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:storage |
-20°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:technology |
vaccine
|
| gptkbp:WHOEmergencyUseListing |
2021-04-30
|
| gptkbp:bfsParent |
gptkb:Vaccine_Research_Center
|
| gptkbp:bfsLayer |
6
|